A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.WALTHAM, Mass., Sept. 14, 2021 /PRNewswire/ -- Skyhawk Therapeutics, Inc. today announced that Fidelity Management & Research Company LLC has led a $133 million oversubscribed investment round in Skyhawk, along with other major investors. This brings total equity funding plus partnership capital in the Company to over $600 million thus far, with potential future milestones of over $20 billion plus ongoing royalties. "This investment round strengthens Skyhawk's capacity to advance our internal pipeline of drug candidates deep into the clinic," said Bill Haney, co-founder and CEO of Skyhawk Therapeutics. "We are delighted that investors support our novel platform, a strong foundation from which to advance a series of our internal drugs for patients, even as we expand our work making drug candidates for our pharma collaborators."   About SkyhawkSkyhawk Therapeutics is committed to discovering, developing and commercializing therapies that use its novel SkySTARTM (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform to build small molecule drugs that bring breakthrough treatments to patients.For more information visit: www.skyhawktx.com, https://twitter.com/Skyhawk_Tx, https://www.linkedin.com/company/skyhawk-therapeutics/SKYHAWK MEDIA CONTACT:Anne Deconinckanne@skyhawktx.comLogo - https://mma.prnewswire.com/media/710814/Skyhawk_Therapeutics_Logo.jpg

in evidenza
Giulia Pelagatti... a tutto sport Talisa Ravagnani, ex star di Amici

Striscia la Notizia, sexy veline

Giulia Pelagatti... a tutto sport
Talisa Ravagnani, ex star di Amici



Testata giornalistica registrata - Direttore responsabile Angelo Maria Perrino - Reg. Trib. di Milano n° 210 dell'11 aprile 1996 - P.I. 11321290154

© 1996 - 2021 Uomini & Affari S.r.l. Tutti i diritti sono riservati

Per la tua pubblicità sul sito: Clicca qui

Contatti

Cookie Policy Privacy Policy

Cambia il consenso

Affaritaliani, prima di pubblicare foto, video o testi da internet, compie tutte le opportune verifiche al fine di accertarne il libero regime di circolazione e non violare i diritti di autore o altri diritti esclusivi di terzi. Per segnalare alla redazione eventuali errori nell'uso del materiale riservato, scriveteci a segnalafoto@affaritaliani.it: provvederemo prontamente alla rimozione del materiale lesivo di diritti di terzi.